Showing results (331-340 of 345) with videos related to

Sort By:
Pageof 35
Lancet Regional Health. Americas|June 27, 2023
Cost-effectiveness analysis of extended thromboprophylaxis with rivaroxaban versus no prophylaxis in high-risk patients after hospitalisation for COVID-19: an economic modelling studyCaroline Cândida Carvalho de Oliveira, Leandro Barile Agati, Camilla Moreira Ribeiro, et al.
Plos One|January 27, 2011
A new approach for heparin standardization: combination of scanning UV spectroscopy, nuclear magnetic resonance and principal component analysisMarcelo A Lima, Timothy R Rudd, Eduardo H C de Farias, et al.
NEJM Evidence|August 26, 2024
Rivaroxaban for Patients with Intermittent ClaudicationEduardo Ramacciotti, Giuliano Giova Volpiani, Karen Falcão Britto, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|April 3, 2024
Biomarkers Profile in Provoked Versus Unprovoked Deep Venous ThrombosisIsabela Rodrigues Tavares, Roberto Augusto Caffaro, Maria Fernanda Portugal, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|October 23, 2025
Biomarker Analysis from the Compass Claudication Study - Rivaroxaban for Intermittent ClaudicationKaren Falcão Britto, Roberto Augusto Caffaro, Giuliano Giova Volpiani, et al.
JAMA|May 20, 2019
Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical TrialJean-Louis Vincent, Bruno Francois, Igor Zabolotskikh, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|December 7, 2022
Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial : Venous thromboembolism prophylAxis after gynecoLogical pElvic cancer surgery with RIvaroxaban versus enoxAparin (VALERIA trial)André Luiz Malavasi Longo de Oliveira, Renata Fernanda de Oliveira Pereira, Leandro Barile Agati, et al.
Critical Care Medicine|August 28, 2013
A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulationJean-Louis Vincent, Mayakonda K Ramesh, David Ernest, et al.
The American Journal of Medicine|April 30, 2016
North American Thrombosis Forum, AF Action Initiative Consensus DocumentChristian T Ruff, Jack E Ansell, Richard C Becker, et al.
Thrombosis and Haemostasis|February 5, 2024
Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus PaperJob Harenberg, Robert C Gosselin, Adam Cuker, et al.
Pageof 35